Patent: 10,010,585

Summary for Patent: 10,010,585

Title:	Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma
Abstract:	Methods to reduce the proliferation of vestibular schwannoma (VS) cells and/or provide neuroprotection to reduce the risk of sensorineural hearing loss (SNHL), vestibular dysfunction and facial nerve paralysis in subjects with VS. The methods can include one or more of decreasing TNF-.alpha. activity or expression; decreasing NF-.kappa.B expression or activity; decreasing COX-2 expression or activity; administering FGF2; decreasing HGF expression or activity; or decreasing c-Met expression or activity.
Inventor(s):	Stankovic; Konstantina (Boston, MA), Dilwali; Sonam (Dallas, TX)
Assignee:	Massachusetts Eye and Ear Infirmary (Boston, MA)
Application Number:	14/741,332
Patent Claims:	see list of patent claims

United States Patent 10,010,585 (Vestibular Schwannoma) Claim Analysis and U.S. Patent Landscape

Executive summary U.S. Patent 10,010,585 centers on local inner-ear administration of a TNF‑alpha inhibitor to treat vestibular schwannoma (VS), with claims spanning (i) diagnosing a subject with VS and (ii) delivering TNF‑alpha inhibitors directly into the ear/inner ear, including optional dosing modalities (eardrum injection). Claim scope is broad on the therapy class (TNF‑alpha inhibitors) but narrower on the indication (vestibular schwannoma) and the route (direct delivery into the inner ear). The patent’s enforceability and licensing value in the U.S. hinges on two axes: (1) prior art on TNF‑alpha inhibition in VS and (2) prior art on local inner-ear delivery of biologics/anti-TNF agents, including tympanic membrane or inner-ear injection protocols.

What is US 10,010,585 claiming for treating vestibular schwannoma with TNF‑alpha inhibitors?

Core claim theme: a method that combines patient identification + local TNF‑alpha inhibitor delivery into the ear/inner ear for vestibular schwannoma.

Claim 1 (broadest operational structure)

Claim 1 recites:

• Method of treating a subject having vestibular schwannoma
• Identifying a subject having VS
• Administering to the ear a therapeutically effective amount of a TNF‑alpha inhibitor
• By direct delivery into the inner ear

This is a method-of-treatment claim with a route-of-administration limitation as the key differentiator versus systemic anti-TNF use.

Claim 2 (disease modification framing)

Claim 2 recites:

• Reducing the rate of vestibular schwannoma tumor growth
• Same patient identification and same local delivery framework

The second claim changes the outcome framing from “treating” to slowing growth, but keeps the same therapeutic agent class and route.

Claim 3 (TNF‑alpha inhibitor species list)

Claim 3 narrows Claim 1 by specifying TNF‑alpha inhibitors selected from:

• adalimumab
• infliximab
• golimumab
• etanercept
• certolizumab

This converts the class-based claim into species-anchored coverage. For licensing and litigation, the list matters because it can align infringement to specific marketed biologics.

Claim 4 (local delivery mechanism: eardrum injection)

Claim 4 limits local administration to injection through the ear drum (tympanic membrane injection).

This introduces a more specific delivery method. In practice, it can reduce freedom-to-operate if competitors rely on alternative inner-ear pathways (e.g., cochleostomy, round window, microcatheter delivery).

Claim 5 (local administration: direct delivery into inner ear)

Claim 5 depends from Claim 2 and specifies:

• direct delivery into the inner ear

Claim 5 tightens Claim 2’s route language.

Claim architecture: what has the tightest infringement hooks

• Most infringement-sensitive element: direct delivery into the inner ear (Claims 1, 2, 5)
• Most design-around-friendly element: the option to shift route away from “direct delivery into the inner ear” and/or avoid tympanic membrane injection (Claim 4)
• Most litigation-friendly element: the anti-TNF agent list in Claim 3 (enumerated species)

How do these claims read on practical anti-TNF biologic use in vestibular schwannoma?

Functional reading:

• A party must perform: (i) identify a VS patient and (ii) deliver a TNF‑alpha inhibitor to the ear with direct inner-ear delivery at a therapeutically effective amount.

Where “therapeutically effective amount” creates proof and causation pressure

In method-of-treatment claims, “therapeutically effective” usually requires evidence of an amount and regimen that yields a clinical effect. For infringement, plaintiffs often rely on:

• clinical or preclinical efficacy data for anti-TNF in the indication
• dosing rationales
• monitoring outcomes tied to tumor growth or symptom improvement

Where “identifying” can create evidentiary friction

“Identifying a subject having vestibular schwannoma” is a standard method-claim preamble that can align with routine diagnostic steps. Defendants may argue that “identifying” is inherent to treating VS patients, but plaintiffs can treat it as a claim step that is satisfied by standard imaging/diagnosis.

What prior art risks threaten US 10,010,585 (anti-TNF + inner-ear delivery + VS)?

Without an exhaustive claim-by-claim citation set, the relevant risk categories are consistent and can be assessed as follows:

Risk category 1: anti-TNF biology in schwannoma or VS

If there is prior art disclosing TNF‑alpha inhibitors for VS (or closely analogous tumor microenvironments with TNF signaling in schwannoma), Claim 1’s novelty may narrow to the route. If prior art instead discloses anti-TNF for tumors broadly, novelty may rest on the specific combination of:

• VS indication
• local inner-ear delivery

Risk category 2: local delivery of biologics into the inner ear

The route element is likely the key novelty lever. Prior art that teaches:

• tympanic membrane injection
• round window or cochlear injection
• intratympanic administration of biologics for inner-ear diseases

can matter if it includes:

• direct inner-ear delivery of antibodies or TNF inhibitors
• protocols for deposition in cochlear/vestibular tissues

If prior art shows that anti-TNF biologics were known candidates for local inner-ear deposition (even for other indications), the remaining novelty becomes the VS treatment use.

Risk category 3: obviousness combinations

Even if prior art does not disclose the full combination, obviousness can be built from:

• known anti-TNF therapy for inflammatory pathways in tumors
• known inner-ear local biologic delivery methods
• known rationale that local delivery improves tissue exposure and reduces systemic exposure

That combination attack is especially plausible for claims where the agent class and delivery route are both familiar.

How would claim scope be attacked in U.S. validity or infringement disputes?

Obviousness (35 U.S.C. §103) attack vectors

Common arguments for this kind of method claim:

1. Anti-TNF inhibitors were known for TNF-driven pathology and tumor-related signaling.
2. Inner-ear local delivery routes were known for biologics.
3. Applying known anti-TNF to VS with known delivery is routine optimization.

The counter for the patentee is the presence of specific technical or therapeutic evidence supporting that anti-TNF has a therapeutic effect in VS and that local delivery to the inner ear is efficacious or non-obvious.

Indefiniteness or claim construction disputes

Potential claim-construction disputes likely include:

• meaning of “direct delivery into the inner ear”
• whether “administering to the ear” + “direct delivery into the inner ear” covers intratympanic vs cochlear implant vs surgically assisted delivery
• whether tympanic membrane injection is encompassed or only falls under Claim 4

Those disputes impact infringement and non-infringement design choices.

Enablement / written description

For species-enumerated claim 3, enablement is typically scrutinized for whether the specification supports the use of each listed TNF inhibitor for the claimed method. If the disclosure is generic to “TNF‑alpha inhibitors,” defendants may argue insufficient support for each enumerated species and their local inner-ear delivery.

Which competitors’ anti-TNF biologics could be within Claim 3 if delivered intratympanically or intra-inner-ear?

Claim 3 lists five TNF‑alpha inhibitors by name. A party practicing the claimed method using any of these agents could face claim 3 exposure if route and indication match.

Potential in-scope biologics under Claim 3 (named):

• adalimumab
• infliximab
• golimumab
• etanercept
• certolizumab

The key infringement question is not commercial availability but the claimed method performance: VS patient + TNF inhibitor + direct inner-ear delivery.

What is the patent estate breadth: how many layers exist around this TNF/inner-ear/VS concept?

US 10,010,585 as described by the provided claims suggests a highly targeted therapeutic and delivery concept. In patent landscapes for inner-ear biologic administration, estates typically split into:

• method-of-treatment (this patent’s core)
• delivery devices or administration steps
• additional indications (hearing loss, vestibular disorders)
• formulation or stabilizer concepts for biologics for local use
• surgical route variants (tympanic membrane vs round window vs cochleostomy)

Because no bibliographic information (assignee, filing date, publication number, related continuations) was provided, the landscape can only be mapped structurally, not enumerated across family members.

When does US 10,010,585 expire in the U.S., and when could generic or biologic competition challenge it?

A timing analysis requires:

• patent filing date (nonprovisional) to compute 20-year term
• any PTA or terminal disclaimers
• whether there are related continuation patents with later expiration
• FDA regulatory status to determine whether relevant exclusivity barriers exist

Those elements are not provided, so a reliable exclusivity/expiration timeline cannot be produced from the claims alone.

What FDA regulatory pathway issues matter for method-of-use claims covering TNF inhibitors for VS?

Method claims like these interact with FDA pathways differently depending on who is seeking approval:

• If the biologic is already approved for another indication, a new VS indication could be pursued via a new FDA submission (label expansion), typically requiring clinical data or bridging.
• For generic biologics (biosimilars) of the listed TNF inhibitors, the product itself may be the same active ingredient but route and indication are governed by labeling and intended use. In practice, infringement of method-of-treatment claims can hinge on off-label use evidence and inducement, not just label wording.

Without FDA labeling and submission/approval history for the specific VS indication, a concrete Orange Book-style status mapping is not computable from the claims provided.

How strong is the patent estate for local TNF inhibition in vestibular schwannoma?

Strength drivers

• The combination of:
  • VS indication
  • TNF‑alpha inhibitor
  • direct inner-ear delivery creates a narrower claim than systemic anti-TNF use.
• Claim 3’s enumerated anti-TNF species supports enforcement against those exact agents.

Weakness drivers

• If prior art exists for inner-ear local biologic delivery (including intratympanic delivery) and TNF inhibition in related tumor/inflammatory contexts, the patent risks being treated as a “known method applied to a predictable use.”
• If claim construction of “direct delivery into the inner ear” is broad, defendants can attempt to design around by using alternative routes that are argued to fall outside the claim scope. Claim 4’s tympanic membrane injection adds a fallback but also creates a specific carve-like vulnerability to alternate delivery methods.

What generic entry risks exist for TNF inhibitors under these claims?

For TNF inhibitors, the “generic” concept usually corresponds to biosimilars. Method-of-treatment claims do not prevent biosimilar approval per se; they can still block:

• clinical practice for labeled or promoted VS use
• inducement and contributory infringement theories tied to training, instructions, or marketing for the claimed method

The practical risk level depends on whether a biosimilar sponsor or clinical investigators would perform the claimed route and indication in the U.S.

What patent litigation questions will decide infringement: route, agent, and indication

For U.S. method claims like these, infringement disputes often compress into three factual/legal points:

1. Route proof

   • Does the administration qualify as “direct delivery into the inner ear”?
   • Is tympanic membrane injection required or optional under the relevant claim?

2. Agent identity

   • Is the administered agent one of the enumerated TNF inhibitors in Claim 3, or a different TNF‑alpha inhibitor that still fits Claim 1’s class?

3. Indication and patient population

   • Is the subject diagnosed with vestibular schwannoma?
   • Is the “method” actually used to treat or reduce growth rate in VS?

Key Takeaways

• U.S. Patent 10,010,585 claims a method-of-treatment for vestibular schwannoma using TNF‑alpha inhibitors delivered by direct inner-ear administration.
• The claim set is structured to secure both class coverage (TNF‑alpha inhibitors) and species coverage (five named TNF inhibitors), with additional specificity via tympanic membrane injection.
• Enforceability and design-around strategies likely turn on inner-ear delivery route definitions and proof, and on whether the prior art establishes TNF inhibition and local inner-ear biologic delivery as routine combinations for tumor treatment.
• A complete legal landscape including expiration, Orange Book/Bio-Orange Book status, family members, and litigation can’t be determined from the claim text alone.

FAQs

1. Does US 10,010,585 cover intratympanic TNF‑alpha inhibitor delivery for vestibular schwannoma?
   Only if the administration qualifies as “direct delivery into the inner ear” under claim construction.

2. Can a company avoid infringement by using a TNF inhibitor other than the five listed in claim 3?
   Claim 1 still covers “a TNF‑alpha inhibitor” class, so avoiding claim 3 does not necessarily avoid claim 1.

3. If a biosimilar is approved for other TNF indications, can off-label use in VS trigger exposure under a method patent?
   Exposure can arise if the claimed method is performed in the U.S. with the claimed route and indication, and if theories of inducement apply.

4. How important is tympanic membrane injection to infringement for US 10,010,585?
   It is explicitly tied to Claim 4, but Claims 1, 2, and 5 rely on “direct delivery into the inner ear” without requiring tympanic membrane injection.

5. What evidence most often determines infringement for method-of-treatment patents like this?
   Documentation of patient diagnosis (VS), the administered TNF inhibitor identity, and the actual delivery route and technique (inner-ear vs outer-ear approaches).

References

1. United States Patent No. 10,010,585 (claim text provided in prompt).

Details for Patent 10,010,585

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998		2035-06-16
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998		2035-06-16
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999		2035-06-16